Choosing between Clinical Research Exome - CRE V4 and INVIEW Oncoprofiling depends on your research or clinical goals:

• Clinical Research Exome - CRE V4 offers broad coverage of the entire exome, allowing comprehensive detection of variants across all coding regions. It’s ideal if you want to explore a wide range of genes beyond a specific set or discover novel mutations.
• INVIEW Oncoprofiling targets a focused panel of cancer-relevant genes and regions, providing deep coverage optimized for known clinically actionable mutations. It’s best suited for targeted cancer diagnostics or when you need high sensitivity in specific genes.

If you require wide discovery and broader variant detection, go with CRE V4. For a targeted, high-depth analysis of established cancer markers, Oncoprofiling is the better choice.